Skip to main content
SpringerLink
Log in

Hormone Replacement Therapy after Gynaecological Cancer

  • Chapter
  • First Online:
Fundamentals in Gynaecologic Malignancy

  • 421 Accesses

Abstract

Female hormones and their optimal level play a pivotal role in a woman’s ability to smoothly carry out her daily activities. There is significant data in the literature that hormones affect the biochemical and physiological functions and have a more profound impact on her psychosocial interactions and existence, increased risk of overall mortality, cardiovascular diseases, neurological diseases, psychiatric diseases, osteoporosis, and other sequelae [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65:161–6.

    Article  Google Scholar 

  2. Biliatis I, Thomakos N, Rodolakis A, Akrivos N, Zacharakis D, Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. J Obstet Gynaecol. 2012;32:321–5.

    Article  CAS  Google Scholar 

  3. Molassiotis A, Chan CWH, Yam BMC, Chan SJ. Quality of life in Chinese women with gynaecological cancers. Support Care Cancer. 2000;8(5):414–22.

    Article  CAS  Google Scholar 

  4. Guidelines N. Survivorship. Natl Compr Cancer Netw [Internet]. 2021. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf.

  5. Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by the north American Meno. Gynecol Oncol. 2020;157(2):303–6.

    Article  CAS  Google Scholar 

  6. Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int. 2010;16:89–93.

    Article  Google Scholar 

  7. Hulley SB, Grady D. The WHI estrogen-alone trial—do things look any better? JAMA. 2004;291:1769–71.

    Article  CAS  Google Scholar 

  8. Manson JAE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310(13):1353–68.

    Article  CAS  Google Scholar 

  9. Jaursch-Hancke C. Online-Datenbank mit Autoren-und Stichwortsuche Androgenmangel bei Frauen: Wann klinisch relevant? Neuroimaging-Verfahren in der Adipositasforschung Androgenmangel bei Frauen: Wann klinisch relevant? Austrian. J Clin Endocrinol Metab. 2011;4(3):12–6. www.kup.at/klinendokrinologie.

    CAS  Google Scholar 

  10. Lin H, Fu HC, Wu CH, Tsai YJ, Chou YJ, Shih CM, et al. Evaluation of sexual dysfunction in gynecologic cancer survivors using DSM-5 diagnostic criteria. BMC Womens Health. 2022;22(1):1–7.

    Article  Google Scholar 

  11. Vistad I, Cvancarova M, Fosså SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians’ assessments agree with those of their patients? Int J Radiat Oncol. 2008;71(5):1335–42.

    Article  Google Scholar 

  12. Kapoor E, Benrubi D, Faubion SS. Menopausal hormone therapy in gynecologic cancer survivors: a review of the evidence and practice recommendations. Clin Obstet Gynecol. 2018;61:488–95.

    Article  Google Scholar 

  13. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer. 1996;67:327–32.

    Article  CAS  Google Scholar 

  14. Eeles RA, Tan S, Wiltshaw E, Fryatt I, A’Hern RP, Shepherd JH, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. Br Med J. 1991;302(6771):259–62.

    Article  CAS  Google Scholar 

  15. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer. 1999;86(6):1013–8.

    Article  CAS  Google Scholar 

  16. Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis, and ovarian cancer survival. Int J Cancer. 2006;119(12):2907–15.

    Article  CAS  Google Scholar 

  17. Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors—review of the literature. Pathol Oncol Res. 2020;26:63–78.

    Article  CAS  Google Scholar 

  18. Buttarelli M, Mascilini F, Zannoni GF, Ciucci A, Martinelli E, Filippetti F, et al. Hormone receptor expression profile of low-grade serous ovarian cancers. Gynecol Oncol. 2017;145(2):352–60.

    Article  CAS  Google Scholar 

  19. Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. Eur J Cancer. 2019;116:35–44.

    Article  CAS  Google Scholar 

  20. Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev. 2020;1:CD012559.

    Google Scholar 

  21. Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin Oncol. 2015;33(35):4138–44.

    Article  CAS  Google Scholar 

  22. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–99.

    Article  CAS  Google Scholar 

  23. Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol. 2019;153:192–200.

    Article  CAS  Google Scholar 

  24. Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059–65.

    Article  Google Scholar 

  25. Langdon SP, Herrington CS, Hollis RL, Gourley C. Estrogen signaling and its potential as a target for therapy in ovarian cancer. Cancers (Basel). 2020;12(6):1–17.

    Article  Google Scholar 

  26. Rees M, Angioli R, Coleman RL, Glasspool RM, Plotti F, Simoncini T, et al. European menopause and Andropause society (EMAS) and international gynecologic cancer society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Int J Gynecol Cancer. 2020;30(4):428–33.

    Article  Google Scholar 

  27. Londero AP, Parisi N, Tassi A, Bertozzi S, Cagnacci A. Hormone replacement therapy in endometrial cancer survivors: a meta-analysis. J Clin Med. 2021;10(14):128.

    Article  Google Scholar 

  28. Lobo F, Thomas E. Type II endometrial cancers: a case series. J Midlife Health. 2016;7(2):69–72.

    Google Scholar 

  29. del Carmen MG, Rice LW. Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol. 2017;146(2):427–35.

    Article  Google Scholar 

  30. Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors—review of the literature. Pathol Oncol Res. 2020;26(1):63–78.

    Article  CAS  Google Scholar 

  31. Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, et al. Hormonal therapy in uterine sarcomas. Cancer Med. 2019;8(4):1339.

    Article  Google Scholar 

  32. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820–30.

    Article  Google Scholar 

  33. Guidozzi F. Estrogen therapy in gynecological cancer survivors. Climacteric. 2013;16(6):611–7.

    Article  CAS  Google Scholar 

  34. del Carmen MG, Rice LW. Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol. 2017;146:427–35.

    Article  Google Scholar 

  35. Nicole McMillian N, Angela Motter M, Frederick P, Gaffney DK, George S, Giuntoli RI, et al. NCCN Guidelines Version 1.2022 Uterine Neoplasms Continue NCCN Guidelines. 2021. https://www.nccn.org/home/member-. Accessed 6 Nov 2021.

  36. Nakanishi T, Wakai K, Ishikawa H, Nawa A, Suzuki Y, Nakamura S, et al. A comparison of ovarian metastasis between squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol. 2001;82(3):504–9.

    Article  CAS  Google Scholar 

  37. Jiao XB, Hu J, Zhu LR. The safety of ovarian preservation in early-stage adenocarcinoma compared with squamous cell carcinoma of uterine cervix. Int J Gynecol Cancer. 2016;26(8):1510–4.

    Article  Google Scholar 

  38. Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res. 2010;30(4):1341–5.

    CAS  Google Scholar 

  39. Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer—a systematic review & meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;247:163–75.

    Article  Google Scholar 

  40. Cervical Cancer and Hormonal Contraceptives. Collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609–21. http://www.thelancet.com/article/S0140673607616845/fulltext.

    Article  Google Scholar 

  41. Lacey JV, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol. 2000;77(1):149–54.

    Article  CAS  Google Scholar 

  42. Vargiu V, Amar ID, Rosati A, Dinoi G, Turco LC, Capozzi VA, et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric. 2021;24(2):120–7.

    Article  CAS  Google Scholar 

  43. Robinson Z, Edey K, Murdoch J. Invasive vulval cancer. Obstet Gynaecol Reprod Med. 2011;21(5):129–36.

    Article  Google Scholar 

  44. Gajjar K, Shafi M. Invasive vulval cancer. Obstet Gynaecol Reprod Med. 2014;24(6):177–85.

    Article  Google Scholar 

  45. Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas. 2010;65(3):190–7.

    Article  CAS  Google Scholar 

  46. Kuhle CL, Kapoor E, Sood R, Thielen JM, Jatoi A, Faubion SS. Menopausal hormone therapy in cancer survivors: a narrative review of the literature. Maturitas. 2016;92:86–96.

    Article  CAS  Google Scholar 

  47. Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int. 2010;16(2):89–93.

    Article  Google Scholar 

  48. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(Suppl. 6):7–12.

    Article  Google Scholar 

  49. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453–5.

    Article  CAS  Google Scholar 

  50. Lupo M, Dains JE, Madsen LT. Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J Adv Pract Oncol. 2015;6(4):322.

    Google Scholar 

  51. Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, et al. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol. 2007;25(28):4438–44.

    Article  Google Scholar 

  52. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The effects of Tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697–708.

    Article  CAS  Google Scholar 

  53. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135–46.

    Article  CAS  Google Scholar 

  54. Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: liberate trial bone substudy. Breast Cancer Res. 2012;14(1):1–11.

    Article  Google Scholar 

  55. Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients - data from LIBERATE trial. Maturitas. 2011;70(4):365–72.

    Article  CAS  Google Scholar 

  56. van Barele M, Heemskerk-Gerritsen BAM, Louwers YV, Vastbinder MB, Martens JWM, Hooning MJ, et al. Estrogens and progestogens in triple negative breast cancer: do they harm? Cancers (Basel). 2021;13(11):1–17.

    Google Scholar 

  57. Schrijver WAME, Suijkerbuijk KPM, Van Gils CH, Van Der Wall E, Moelans CB, Van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(6):568–80.

    Article  Google Scholar 

  58. Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on womens midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50.

    Article  CAS  Google Scholar 

  59. Murthy V, Chamberlain RS. Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Cancer Control. 2012;19(4):317–29.

    Article  Google Scholar 

  60. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health. 2012;8:543–55.

    CAS  Google Scholar 

  61. Overview | Menopause: diagnosis and management | Guidance | NICE. https://www.nice.org.uk/guidance/NG23. Accessed 4 Apr 2022.

  62. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92(3):1018–24.

    Article  CAS  Google Scholar 

  63. Mirkin S, Pinkerton JV, Kagan R, Thompson JR, Pan K, Pickar JH, et al. Gynecologic safety of conjugated estrogens plus Bazedoxifene: pooled analysis of five phase 3 trials. J Womens Health. 2016;25(5):431–42. https://www.liebertpub.com/doi/abs/10.1089/jwh.2015.5351.

    Article  Google Scholar 

  64. Armeni E, Lambrinoudaki I, Ceausu I, Depypere H, Mueck A, Pérez-López FR, et al. Maintaining postreproductive health: a care pathway from the European menopause and Andropause society (EMAS). Maturitas. 2016;89:63–72.

    Article  Google Scholar 

  65. Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–53.

    Article  Google Scholar 

  66. Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J, et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas. 2015;82(3):308–13.

    Article  Google Scholar 

  67. Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339–53.

    Article  Google Scholar 

  68. Holton M, Thorne C, Goldstein AT. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. Expert Opin Pharmacother. 2020;21(4):409–15.

    Article  CAS  Google Scholar 

  69. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623–30.

    Article  Google Scholar 

  70. Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother. 2015;16(17):2703–14.

    Article  CAS  Google Scholar 

  71. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol. 1994;84(2):215–8.

    CAS  Google Scholar 

  72. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JAV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.

    Article  CAS  Google Scholar 

  73. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43–73.

    Article  Google Scholar 

  74. Szabo RA, Marino JL, Hickey M. Managing menopausal symptoms after cancer. Climacteric. 2019;22:572–8.

    Article  CAS  Google Scholar 

  75. Elkins G, Marcus J, Stearns V, Perfect M, Rajab MH, Ruud C, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26(31):5022.

    Article  Google Scholar 

  76. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause. 2013;20(3):291–8.

    Article  Google Scholar 

  77. Dodin S, Blanchet C, Marc I, Ernst E, Wu T, Vaillancourt C, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev. 2013;2013(7):151.

    Google Scholar 

  78. Newton KM, Reed SD, Guthrie KA, Sherman KJ, Booth-Laforce C, Caan B, et al. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause. 2014;21(4):339–46.

    Article  Google Scholar 

  79. Sternfeld B, Guthrie KA, Ensrud KE, Lacroix AZ, Larson JC, Dunn AL, et al. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause. 2014;21(4):330–8.

    Article  Google Scholar 

  80. Franco OH, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA. 2016;315:2554–63.

    Article  CAS  Google Scholar 

  81. Li T, Zhang Y, Cheng Q, Hou M, Zheng X, Zheng Q, et al. Quantitative study on the efficacy of acupuncture in the treatment of menopausal hot flashes and its comparison with nonhormonal drugs. Menopause. 2021;28(5):564–72.

    Article  Google Scholar 

  82. Stubbs C, Mattingly L, Crawford SA, Wickersham EA, Brockhaus JL, McCarthy LH. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. J Okla State Med Assoc. 2017;110(5):272.

    Google Scholar 

  83. Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, et al. Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas. 2020;135:82–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynaecologic Oncology, Dr. Bhubaneswar Borooah Cancer Institute (A Unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Eshwarya Jessy Kaur, Upasana Baruah & Amal Chandra Kataki

  2. Department of Gynaecological Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India

    Amita Maheshwari

Authors
  1. Eshwarya Jessy Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Upasana Baruah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amita Maheshwari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amal Chandra Kataki
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Gynaecologic Oncology, Dr Bhubaneswar Borooah Cancer Institute (A unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Amal Chandra Kataki

  2. Department of Gynaecologic Oncology, Dr Bhubaneswar Borooah Cancer Institute (A unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Debabrata Barmon

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaur, E.J., Baruah, U., Maheshwari, A., Kataki, A.C. (2022). Hormone Replacement Therapy after Gynaecological Cancer. In: Kataki, A.C., Barmon, D. (eds) Fundamentals in Gynaecologic Malignancy. Springer, Singapore. https://doi.org/10.1007/978-981-19-5860-1_26

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5860-1_26

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5859-5

  • Online ISBN: 978-981-19-5860-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation